Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Spero Therapeutics (SPRO) EBITDA Margin (2016 - 2025)

Spero Therapeutics (SPRO) has disclosed EBITDA Margin for 10 consecutive years, with 135.65% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBITDA Margin rose 239.0% year-over-year to 135.65%, compared with a TTM value of 140.17% through Sep 2025, down 13768.0%, and an annual FY2024 reading of 271.46%, down 271583.0% over the prior year.
  • EBITDA Margin was 135.65% for Q3 2025 at Spero Therapeutics, down from 17.22% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 3180.93% in Q3 2021 and bottomed at 13292.71% in Q1 2022.
  • Average EBITDA Margin over 5 years is 1768.56%, with a median of 322.9% recorded in 2024.
  • The sharpest move saw EBITDA Margin surged 5304935bps in 2021, then tumbled -1302670bps in 2022.
  • Year by year, EBITDA Margin stood at 189.35% in 2021, then soared by 196bps to 181.45% in 2022, then plummeted by -1838bps to 3154.1% in 2023, then skyrocketed by 91bps to 289.17% in 2024, then skyrocketed by 53bps to 135.65% in 2025.
  • Business Quant data shows EBITDA Margin for SPRO at 135.65% in Q3 2025, 17.22% in Q2 2025, and 250.78% in Q1 2025.